Title: PULSE GENERATOR SYSTEM AND METHOD

Abstract: A system and method for providing pacing pulses after a cardioversion/defibrillation shock, where the pacing pulses have a pacing rate at an initial value. The pacing rate is decreased from the initial value until at least one intrinsic cardiac contraction is detected. In one embodiment, the pacing rate is decreased by a set amount after pacing a set number of cardiac cycles. Providing the set number of pacing pulses and decreasing the pacing rate by the set amount is then repeated until at least one intrinsic cardiac contraction is detected. An intrinsic cardiac rate is then determined from the at least one intrinsic cardiac contraction. The pacing rate is then increased and maintained to be above (i.e., greater than) the intrinsic cardiac rate.
Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
PULSE GENERATOR SYSTEM AND METHOD

Technical Field

This document relates generally to cardiac rhythm management systems.

Background

When functioning properly, the human heart maintains its own intrinsic rhythm, and is capable of pumping adequate blood throughout the body’s circulatory system. However, some people have irregular cardiac rhythms, referred to as cardiac arrhythmias. Such arrhythmias result in diminished blood circulation. One mode of treating cardiac arrhythmias uses drug therapy. Drug therapy is not always effective for treating arrhythmias of certain patients. For such patients, an alternative mode of treatment is needed. One such alternative mode of treatment includes the use of a cardiac rhythm management system. Such systems are often implanted in the patient and deliver therapy to the heart.

Cardiac rhythm management systems include, among other things, pacemakers, also referred to as pacers. Pacers deliver timed sequences of low energy electrical stimuli, called pace pulses, to the heart, such as via a transvenous lead wire or catheter (referred to as a “lead”) having one or more electrodes disposed in or about the heart. Heart contractions are initiated in response to such pace pulses (this is referred to as “capturing” the heart). By properly timing the delivery of pace pulses, the heart can be induced to contract in proper rhythm, greatly improving its efficiency as a pump. Pacers are often used to treat patients with bradyarrhythmias, that is, hearts that beat too slowly, or irregularly.

Cardiac rhythm management systems also include cardioverters or defibrillators that are capable of delivering higher energy electrical stimuli to the heart. Defibrillators are often used to treat patients with tachyarrhythmias, that is, hearts that beat too quickly. Such too-fast heart rhythms also cause diminished blood circulation because the heart isn’t allowed sufficient time to fill with blood before contracting to expel the blood. Such pumping by the heart is inefficient. A defibrillator is capable of delivering an high energy electrical stimulus that is sometimes referred to as a defibrillation shock. The shock
interrupts the tachyarrhythmia, allowing the heart to reestablish a normal rhythm
for the efficient pumping of blood. In addition to pacers, cardiac rhythm
management systems also include, among other things, pacer/defibrillators that
combine the functions of pacers and defibrillators, drug delivery devices, and
any other systems or devices for diagnosing or treating cardiac arrhythmias.

One problem faced by cardiac rhythm management systems is the proper
treatment of atrial tachyarrhythmias, such as atrial fibrillation. Atrial fibrillation
is a common cardiac arrhythmia which reduces the pumping efficiency of the
heart, though not to as great a degree as in ventricular fibrillation. However, this
reduced pumping efficiency requires the ventricle to work harder, which is
particularly undesirable in sick patients that cannot tolerate additional stresses.
As a result of atrial fibrillation, patients must typically limit their activity and
exercise.

Although atrial fibrillation, by itself, is usually not life-threatening,
prolonged atrial fibrillation may be associated with strokes, which are thought to
be caused by blood clots forming in areas of stagnant blood flow. Treating such
blood clots requires the use of anticoagulants. Atrial fibrillation may also cause
pain, dizziness, and other irritation to the patient. For this reason, atrial
fibrillation is typically treated with a low energy defibrillation shock to enable
the resumption of normal atrial heart rhythms.

An even more serious problem, however, is the risk that atrial fibrillation
may induce irregular ventricular heart rhythms by processes that are yet to be
fully understood. Such induced ventricular arrhythmias compromise pumping
efficiency even more drastically than atrial arrhythmias and, in some instances,
may be life-threatening. Moreover, treating atrial fibrillation by a defibrillation
shock may also induce dangerous ventricular arrhythmias. For these and other
reasons, there is a need for safe and more effective atrial therapy that prevents
the occurrence of atrial tachyarrhythmias, such as atrial fibrillation, thereby
avoiding inducing ventricular arrhythmia as the result of the atrial
tachyarrhythmia or its treatment.
Summary

The present subject matter provides a system and method to address the aforementioned problems. In one embodiment, the present subject matter provides a post-defibrillation shock therapy or post-cardioversion therapy which may prevent or slow the recurrence of the arrhythmia which necessitated the shock. Pacing pulses are delivered at an elevated rate relative to normal intrinsic rates after delivering a defibrillation or cardioversion shock. The pacing pulses delivered at this rate initiate and control the contraction of the heart at a rate that is at or just above the heart’s own intrinsic rate. By controlling and initiating the cardiac contractions the likelihood of the arrhythmia which necessitated the shock returning is reduced.

In one embodiment, the present system provides for post-defibrillation/cardioversion shock pacing pulses to be delivered to the cardiac region having received the shock. The system begins by delivering the pacing pulses at a predetermined time after the defibrillation shock or cardioversion pulse has been delivered. Alternatively, pacing pulses of the present subject matter are delivered after treating the heart with antitachycardia pacing. The pacing pulses are initially delivered at a pacing rate having an initial value. In one embodiment, the initial value is set well above the intrinsic cardiac rate of the patient. This ensures that the pacing rate used by the system will control the rate and the refractory period of the heart. In one embodiment, the pacing rate has an initial value set in the range of 100 to 200 pacing pulses per minute.

The rate of the pacing pulses is decreased from the initial value down to a point where the intrinsic rate of the heart is detected. In one embodiment, the decrease in the pacing rate occurs as a function of delivered pacing pulses. For example, the pacing rate is decreased by a set amount after a set number of cardiac cycles, where the set number of cardiac cycles is a programmable number. In one embodiment, the set number of cardiac cycles paced and the decrease in the pacing rate by the set amount is repeated until at least one intrinsic contraction is detected.

As the pacing rate is being decreased, the system senses for the intrinsic cardiac contraction from the paced chamber. Once the intrinsic contraction is
sensed, an intrinsic cardiac rate is determined. In one embodiment, the intrinsic cardiac rate is determined between the paced event and the intrinsic event. Alternatively, the intrinsic cardiac rate is determined between two consecutive intrinsic events (e.g., sensed contractions). The pacing rate is then increased to be above the intrinsic rate, where the pacing rate is then maintained just above the intrinsic rate.

These and other features and advantages of the present system will become apparent from the following description of example embodiments.

**Brief Description of the Drawings**

- Figure 1 is a flow chart illustrating one embodiment of the present subject matter.
- Figure 2 is a flow chart illustrating one embodiment of the present subject matter;
- Figure 3 is a graph of illustrating one embodiment of the present subject matter;
- Figure 4 is a schematic view of one embodiment of an implantable medical device according to one embodiment of the present subject matter;
- Figure 5 is a schematic view of one embodiment of an implantable medical device according to one embodiment of the present subject matter; and
- Figure 6 is a block diagram of one embodiment of an implantable medical device according to the present subject matter.

**Detailed Description**

In the following detailed description, references are made to the accompanying drawings that illustrate specific embodiments in which the invention may be practiced. Electrical, mechanical, programmatic and structural changes may be made to the embodiments without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense and the scope of the present invention is defined by the appended claims and their equivalents.

Providing pacing pulses to a cardiac chamber soon after a defibrillation shock or a cardioversion pulse is delivered may prevent or slow the recurrence of the arrhythmia which necessitated the shock. It has been found that delivering
pacing pulses at an elevated rate relative to normal intrinsic rates allows for the rhythm of the heart to be better controlled and the likelihood that an arrhythmia will reoccur lessened. For example, after delivering a defibrillation shock a cardiac chamber is paced at an elevated rate for a period of time, after which the pacing rate is gradually reduced (smoothing the pacing rate) down to the point where the pacing is stopped and the heart’s intrinsic rhythm is allowed to resume control. By providing pacing pulses to the cardiac chamber, not only can the contraction rate of the heart be controlled, but the refractory periods of the chamber can be regularized. Regularizing the refractory periods of the cardiac chamber is important in maintaining sinus rhythm (i.e., normal rhythm) of the heart. Once the pacing is stopped, and the heart’s own intrinsic rhythm takes over, there is an increased opportunity for irregular refractory periods to occur. Irregular refractory periods increase the chances that the arrhythmia, (e.g., fibrillation or tachycardia) will return. Thus, maintaining pacing control over the heart after a defibrillation shock or cardioversion pulse is important in ensuring that the heart maintains sinus rhythm.

One difficulty with maintaining pacing control over the cardiac chamber is balancing the heart’s own intrinsic rate with what elevated pacing rate to use in maintaining control. Provide a pacing rate that is too much above the intrinsic rate may not be desirable for both the patient and for the longevity of the implantable device. Therefore, a system which would allow for elevated pacing, post-defibrillation shock or cardioversion pulse, which would smooth to a pacing rate at or just above the heart’s own intrinsic rate is needed.

The present subject matter offers such a system. In one embodiment, the present system provides for post-defibrillation cardioversion shock pacing pulses to be delivered to the cardiac region having received the shock. The pacing pulses are initially delivered at a pacing rate having an initial value. In one embodiment, the initial value is set well above the intrinsic cardiac rate of the patient. This ensures that the pacing rate used by the system will control the rate and the refractory period of the heart.

In one embodiment, the system begins by delivering the pacing pulses at a predetermined time after a defibrillation shock or cardioversion pulse has been
delivered. Alternatively, pacing pulses of the present subject matter are delivered after treating the heart with antitachycardia pacing. The rate of the pacing pulses is then decreased from the initial value down to a point where the intrinsic rate of the heart is detected. In one embodiment, the decrease in the pacing rate occurs as a function of delivered pacing pulses, where the pacing rate is decreased by a set amount after a set number of cardiac cycles, where the set number of cardiac cycles is a programmable number.

As the pacing rate is being decreased, the system senses for an intrinsic cardiac contraction from the paced chamber. Once the intrinsic contraction is sensed, an intrinsic cardiac rate is determined. In one embodiment, the intrinsic cardiac rate is determined between the paced event and the intrinsic event. Alternatively, the intrinsic cardiac rate is determined between two consecutive intrinsic events (e.g., at least two sensed intrinsic contractions, such as intrinsic atrial contractions or intrinsic ventricular contractions). The pacing rate is then increased to be above the intrinsic rate, where the pacing rate is then maintained just above the intrinsic rate, as will be more fully described below.

Referring now to Figure 1, there is shown one embodiment of a method according to the present subject matter. At 100, an cardiac signal is sensed from one or more cardiac chambers of the heart. In one embodiment, the cardiac signal is either a unipolar signal or a bipolar signal sensed with one or more electrodes implanted within the heart. At 110, the cardiac signal is analyzed to detect an arrhythmia, such as a fibrillation or a tachycardia episode. If an arrhythmia is not detected, the method continues to sense and analyze the cardiac signal. If, however, an arrhythmia is detected, one or more defibrillation shocks, or cardioversion pulses, are used to capture and convert the heart 120. Alternatively, under the appropriate circumstances, antitachycardia pacing is delivered to convert the arrhythmia (e.g., ventricular tachycardia) by stimulating the heart with a rapid series of electrical pulses.

Once captured and converted, pacing pulses having a pacing rate at an initial value are provided to the heart at 130. In one embodiment, the first pacing pulse of the pacing pulses is provided at a delay after the defibrillation or cardioversion shock. In one embodiment, the delay is programmable in the
range of 0 milliseconds to 1000 milliseconds. In an additional embodiment, the delay is programmable in the range of 0 milliseconds to 500 milliseconds. These given time ranges for delay, however, are exemplary and other time ranges which exceed 1000 milliseconds are considered within the scope of the present subject matter.

In an additional embodiment, the initial value of the pacing rate is set (programmed) at a value equal to or less than the maximum programmable pacing rate value of the implantable pacemaker in which the present subject matter is implemented. For example, the initial value of the pacing rate is set in the range of 100 to 200 pacing pulses per minute (interval durations of 600 to 300 milliseconds). In one embodiment, setting the initial value of the pacing rate includes either fixing the value of the pacing rate or allowing the pacing rate to be a programmable value. In one embodiment, the initial value of the pacing rate is a programmable value that is set above the intrinsic cardiac rate of the patient, where the intrinsic cardiac rate of the patient is determined by the patient’s physician. Alternatively, the initial value of the pacing rate is preset and is not adjustable.

The initial value of the pacing rate is used in pacing the heart for a set number of cardiac cycles. In one embodiment, the set number of cardiac cycles is a programmable value in the range of two (2) to one-hundred twenty eight (128) cardiac cycles. Once the heart has been paced at the pacing rate initial value for the set number of cardiac cycles, the pacing rate is then decreased at 140. In one embodiment, the pacing rate is decreased by a set amount for every subsequent set of the number of cardiac cycles until an intrinsic cardiac contraction is detected. Thus, providing the set number of pacing pulses and then decreasing the pacing rate by the set amount is repeated until an intrinsic cardiac contraction is detected. In other words, the pacing rate for each of the set number of cardiac cycles becomes slower and slower, until an intrinsic cardiac contraction is detected.

The pacing rate is then decreased by adding a set value to the interval duration between the pacing pulses. In one embodiment, the set value is in the range of seven and one-half (7.5) milliseconds to ten (10) milliseconds. Thus,
for an initial pacing rate of 200 pacing pulses per minute and a set value of 10 milliseconds, after the first decrease the pacing rate would be approximately 193.5 pacing pulses per minute, after the second decrease the pacing rate would be approximately 187.5 pacing pulses per minute, and so forth until an intrinsic cardiac contraction is detected. In an alternative embodiment, the set value includes additional values which allow for changes to the pacing rate according to the present subject matter (e.g., set values less than 7.5 milliseconds and set values greater than 10 milliseconds).

At 150, once the intrinsic contraction is detected, an intrinsic cardiac rate is determined. In one embodiment, the intrinsic cardiac rate is the rate determined from the time interval between the paced cardiac event and the subsequent intrinsic cardiac event. In an alternative embodiment, the intrinsic rate is determined from two consecutive sensed intrinsic cardiac contractions. Once the intrinsic cardiac rate is determined at 150, the pacing rate is increased at 160 to be greater than the intrinsic cardiac rate. In one embodiment, the pacing rate is increased by subtracting the value to the interval duration between the pacing pulses. Thus, once the intrinsic rate is determined the cardiac pacing rate is increased by the margin of the value so the pacing pulses control the contraction of the heart, and not the intrinsic mechanisms of the heart (i.e., the SA-node). The increased pacing rate is then used in delivering the pacing pulse after the intrinsic pulse is detected.

The system then returns to 140, where the pacing rate is allowed decrease as previously described until the next intrinsic contraction is detected. The system then proceeds to 150, where the intrinsic rate is determined as previously described. The system then proceed through 160 and back to 140. This allows the heart to be paced at, or nearly at, the intrinsic rate, while still being under the control of a pulse generator. Thus, the pacing rate is maintained at or above the intrinsic cardiac rate. As previously discussed, this allows the refractory period of the cardiac chamber to be controlled so as to reduce the likelihood of recurrence of the arrhythmia or tachyarrhythmia.

The post-shock therapy of the present subject matter is then discontinued after a predetermined time interval. In one embodiment, the predetermined time
interval is a programmable or a set value of up to 15 minutes. After the predetermined time interval expires, the system resumes any previously suspended pacing protocols and returns to sense the cardiac signal from one or more cardiac chambers of the heart at 100. Alternatively, the post-shock therapy according to the present subject matter is discontinued and the system returns to 100 after a predetermined number of intrinsic pulses are detected. In one embodiment, the predetermined number of intrinsic pulses is programmed or set in the range of 0 to 15 sensed intrinsic pulses.

Referring now to Figure 2, there is shown an additional embodiment of a method according to the present subject matter. The embodiment of Figure 2 is specific to atrial arrhythmias and where pacing pulses are delivered to the atrium. It will be appreciated that the present subject matter can be applied to other cardiac regions, including, but not limited to, ventricular chambers of the heart (e.g., right and/or left ventricles) and/or atrial chambers of the heart (e.g., right and/or left atria).

At 200, an atrial signal is sensed from the atrium. In one embodiment, the atrial signal is either a unipolar signal or a bipolar signal sensed with one or more electrodes implanted within the heart. At 210, the atrial signal is analyzed to detect an atrial fibrillation or atrial tachycardia. In one embodiment, the atrial rate is used as a criteria for determining the presence of an atrial fibrillation and/or atrial tachycardia. Other techniques of determining the occurrence of atrial fibrillation and/or atrial tachycardia are possible. If an atrial fibrillation or tachycardia are not detected, the method continues to sense and analyze the atrial signal. If an atrial fibrillation or tachycardia is detected, one or more atrial defibrillation shocks, or atrial cardioversion pulses, are used to capture and convert the atrial chambers at 220.

Once captured and converted, pacing pulses having a pacing rate at an initial value are provided to the atrium at 230. In one embodiment, a first pacing pulse of the pacing pulses is provided at a delay after the defibrillation or cardioversion shock. In one embodiment, the delay is programmable in the range of 0 milliseconds to 1000 milliseconds. In an additional embodiment, the delay is programmable in the range of 0 milliseconds to 500 milliseconds. These
given time ranges for delay, however, are exemplary and other time ranges which exceed 1000 milliseconds are considered within the scope of the present subject matter.

In an additional embodiment, the initial value of the pacing rate is set (programmed) at a value equal to or less than the maximum programmable pacing rate value of the implantable pacemaker in which the present subject matter is implemented. For example, the initial value of the pacing rate is set in the range of 100 to 200 pacing pulses per minute (interval durations of 600 to 300 milliseconds). In one embodiment, setting the initial value of the pacing rate includes either fixing the value of the pacing rate or allowing the pacing rate to be a programmable value. In one embodiment, the initial value of the pacing rate is a programmable value that is set above the intrinsic cardiac rate of the patient, where the intrinsic cardiac rate of the patient is determined by the patient's physician. Alternatively, the initial value of the pacing rate is preset and is not adjustable.

The initial value of the pacing rate is used in pacing the atrium for a set number of cardiac cycles. In one embodiment, the number of cardiac cycles is a programmable value in the range of two (2) to one-hundred twenty eight (128) cardiac cycles. Once the atrium has been paced at the pacing rate initial value for the set number of cardiac cycles, the pacing rate is then decreased at 240. In one embodiment, the pacing rate is decreased by a set amount for every subsequent set of the set number of cardiac cycles until an intrinsic atrial contraction is detected. Thus, providing the set number of pacing pulses and then decreasing the pacing rate by the set amount is repeated until an intrinsic atrial contraction is detected. In other words, the pacing rate for each group of the set number of cardiac cycles becomes slower and slower, until an intrinsic atrial contraction is detected. In one embodiment, the pacing rate is decreased by adding the value to the interval duration between the pacing pulses, where the value is in the range of seven and one-half (7.5) milliseconds to ten (10) milliseconds. Thus, for an initial pacing rate of 200 pacing pulses per minute and a set value of 10 milliseconds, after the first decrease the pacing rate would be approximately 193.5 pacing pulses per minute, after the second decrease the
pacing rate would be approximately 187.5 pacing pulses per minute, and so forth until an intrinsic cardiac contraction is detected. In an alternative embodiment, the set value includes additional values which allow for changes to the pacing rate according to the present subject matter (e.g., set values less than 7.5 milliseconds and set values greater than 10 milliseconds).

At 250, once the intrinsic contraction is detected, an intrinsic atrial rate is determined. In one embodiment, the intrinsic atrial rate is the rate determined from the time interval between paced atrial event and the subsequent intrinsic atrial event. In an alternative embodiment, the intrinsic rate is determined from two consecutive sensed intrinsic atrial contractions. Once the intrinsic atrial rate is determined at 250, the pacing rate is increased at 260 to be greater than the intrinsic atrial rate. In one embodiment, the pacing rate is increased by subtracting the value to the interval duration between the pacing pulses. Thus, once the intrinsic rate is determined the atrial pacing rate is increased by the margin of the value so the pacing pulses control the contraction of the atrium, and not the intrinsic mechanisms of the heart (i.e., the SA-node). The increased pacing rate is then used in delivering the pacing pulse after the intrinsic pulse is detected.

The system then returns to 240, where the pacing rate is allowed decrease as previously described until the next intrinsic contraction is detected. The system then proceeds to 250, where the intrinsic rate is determined as previously described. The system then proceed through 260 and back to 240. This allows the atrium to be paced at, or nearly at, the intrinsic rate of the atrium, while still being under the control of the pulse generator. Thus, the pacing rate of the atrium is maintained at or above the intrinsic rate of the atrium. As previously discussed, this allows the refractory period of the cardiac chamber to be controlled so as to reduce the likelihood of recurrence of the arrhythmia or tachyarrhythmia.

The post-shock therapy of the present subject matter is then discontinued after a predetermined time interval. In one embodiment, the predetermined time interval is a programmable or a set value of up to 15 minutes. After the predetermined time interval expires, the system resumes any previously
suspended pacing protocols and returns to sense the cardiac signal from one or more cardiac chambers of the heart at 200. Alternatively, the post-shock therapy according to the present subject matter is discontinued and the system returns to 200 after a predetermined number of intrinsic pulses are detected. In one embodiment, the predetermined number of intrinsic pulses is programmed or set in the range of 0 to 15 sensed intrinsic pulses.

Referring now to Figure 3, there is shown an example of a post-therapy pacing response according to the present subject matter. Figure 3 shows a plot of an intrinsic cardiac rate 300 and a pacing rate 310 which are plotted on a rate (beats/time) versus time plot. At 320 a defibrillation or cardioversion shock has been delivered to the heart. No intrinsic cardiac rate is present at this time as the heart is in its refractory period following the shock. Pacing pulses are delivered to the heart after the delay 330, where the pacing pulses are delivered at the initial value 340.

After the set number of paced cardiac cycles 350, the pacing rate is decreased along 360, as previously described. The pacing rate is decreased along 360 as previously described until an intrinsic atrial contraction is detected at 370. Once the intrinsic atrial rate is determined, the pacing rate is then increased at 380 and the pacing rate is maintained at or above the intrinsic rate at 390, as previously described.

In one embodiment, the system of the present subject matter can have a programmable time interval over which the system will operate before the heart is allowed to revert to an intrinsic cardiac rhythm. In one embodiment, the programmable time interval is set in the range of 15 seconds to 1 hour. After this interval, the system would then revert back to any original settings for atrial pacing that might have been programmed into the device.

Referring now to Figure 4, there is shown one embodiment of a cardiac rhythm management system 400 according to the present subject matter. In the present embodiment, the cardiac rhythm management system 400 includes a first cardiac lead 410 having a first electrode 414 and a second electrode 416. In one embodiment, the first electrode 414 is a pace/sense electrode located at or near a distal end 420 of the first cardiac lead 410. The second electrode 416 is also a
pace/sense electrode located proximal the first electrode 414. In one embodiment, the second electrode 416 is a ring electrode which partially or completely encircles the first cardiac lead 410.

In one embodiment, the first electrode 414 is used to sense either a unipolar cardiac signal between the first electrode 414 and the housing 428 of the cardiac rhythm management system 400. Alternatively, the first electrode 414 and the second electrode 416 are used to sense a bipolar cardiac signal. In the present embodiment, the first cardiac lead 410 is a J-tip lead, where the first electrode 414 is located at the distal tip of the lead 410.

The cardiac rhythm management system 400 further includes a second cardiac lead 430. In one embodiment, the second cardiac lead 430 includes a first pace/sense electrode 432, a first defibrillation electrode 434 and a second defibrillation electrode 436. The second cardiac lead 430 is implanted with the distal end of the lead implanted in the right ventricle of the heart, with the first defibrillation electrode 434 located in the right ventricular chamber and the second defibrillation electrode 436 located in the right atrium and/or major vein leading to the right atrium (e.g., superior vena cava). With the second lead 430, ventricular cardiac signals can be sensed between the electrodes. For example, a rate signal (near field signal) is sensed between either the first pace/sense electrode 432 and the first defibrillation electrode 434, or between the first pace/sense electrode 432 and the housing 428. A far field signal can also be sensed between the first and second defibrillation electrodes 434 and 436. In one embodiment, defibrillation and cardioversion pulses are delivered between the first defibrillation electrode 434, and the second defibrillation electrode 436 and the housing 428, as shown by arrows 440. The defibrillation and cardioversion pulses are delivered, in the present example, in response to an atrial arrhythmia as previously described. Alternatively, the defibrillation and/or cardioversion pulses could be delivered in response to a ventricular arrhythmia.

The cardiac rhythm management system 400 includes control circuitry coupled to the first electrode 414 and the second electrode 416 from which a cardiac signal is sensed. The first electrode 414 and the second electrode 416 are shown implanted in a supraventricular region (i.e., atrial region) of the heart,
from which an atrial cardiac signal can be sensed and to which pacing pulses can be delivered according the present subject matter. In one embodiment, pacing pulses can be delivered between either the first electrode 414 and the housing 428 or the first electrode 414 and the second electrode 416. In addition, atrial defibrillation shocks and/or cardioversion pulses can be delivered by the control circuitry between the first defibrillation electrode 434, and the second defibrillation electrode 436 and the housing 428, as shown by arrows 440.

Figure 4 also shows a medical device programmer 444. The medical device programmer 444 and the cardiac rhythm management system 400 include communication circuitry which allows for cardiac data to be to and from the cardiac rhythm management system 400. In addition, command signals for controlling the operation of the cardiac rhythm management system 400 can also be sent between the medical device programmer 444 and the cardiac rhythm management system 400. In one embodiment, communication between the medical device programmer 444 and the cardiac rhythm management system 400 is established over a radio frequency telemetry channel.

Referring to Figure 5, there is shown an additional embodiment of the system shown in Figure 4, where in addition to a first and second cardiac lead 410 and 430, there is shown a third cardiac lead 500 having at least one defibrillation electrode 510. In one embodiment, the third cardiac lead 500 is positioned in a supraventricular location with at least one defibrillation electrode 510 positioned within the coronary sinus and/or great cardiac vein. With the addition of the third cardiac lead 500, cardioversion and/or defibrillation pulses can be delivered between any number of the defibrillation electrodes. For example, cardioversion/defibrillation pulses can be delivered between defibrillation electrode 510 and the second defibrillation electrode 436 and the housing 428. Other shocking patterns are also possible and considered within the scope of the present subject matter.

Referring now to Figure 6, there is shown one embodiment of a cardiac rhythm management system according to the present subject matter. The system includes an implantable cardiac rhythm management device 600, a first cardiac lead 602 and a second cardiac lead 604 (not to scale). In the embodiment shown
in Figure 6, the first cardiac lead 602 is shown with a first electrode 606 and a second electrode 607, and the second cardiac lead 604 is shown with a first electrode 608, a first defibrillation electrode 610 and a second defibrillation electrode 612. In one embodiment, the first electrode 606 and the second electrode 607 are pace/sense electrodes, where the first electrode 606 is a porous tip electrode positioned at a distal end 614 of the first cardiac lead 602 and the second electrode 607 is a ring electrode either partially or completely encircling the first cardiac lead 602 and is positioned proximal to the first electrode 606. The first electrode 608 is also a pace/sense electrode positioned at the distal end 616 of the second cardiac lead 604.

In one embodiment, the first electrode 606 and the second electrode 607 of the first cardiac lead 602 are implanted within the supraventricular region of the heart as previously described. The second cardiac lead 604 is implanted within the heart, where the distal end of the lead 604 is implanted at the apex of the right ventricle to allow the first electrode 608 and the first defibrillation electrode 610 to be within the right ventricular chamber of the heart and the second defibrillation electrode 612 in the supraventricular region of the heart. In one embodiment, the first electrode 608 and the first defibrillation electrode 610 are used to detect a near field signal (a rate signal) and the first defibrillation electrode 610 and the second defibrillation electrode 612 are used to detect a far field signal (a morphology signal) from the heart.

The electrodes are connected to electronic circuitry within the implantable cardiac rhythm management device 600 through lead conductors housed and electrically insulated within the body of the first and second cardiac leads 602 and 604. The lead conductors are coupled to lead connectors on the cardiac leads, which allow for the electrodes positioned on the leads to be coupled to the electronic circuitry through input terminals 620, 622, 624, 626 and 628. In one embodiment, the first and second cardiac leads 602 and 604 have elongated bodies made of one or more materials suitable for implantation in a human body, where such materials are known. Additionally, the electrodes are constructed of electrically conductive materials, such as platinum, platinum-iridium alloys, or other alloys as are known. The lead conductors are also
constructed of electrically conductive materials such as MP35N, an alloy of nickel, chromium, cobalt, and molybdenum.

The implantable cardiac rhythm management device 600 includes control circuitry 630, where the control circuitry 630 is coupled to the electrodes 606, 607, 608, 610 and 612, from which at least a first cardiac signal is sensed, electrical energy pulses are generated under predetermined conditions, and providing electrical energy to electrodes positioned on the leads under the predetermined conditions. In one embodiment, the control circuitry 630 is a programmable microprocessor-based system, with a microprocessor 632 and a memory circuit 634, which contains parameters for various pacing and sensing modes and stores data indicative of cardiac signals received by the control circuitry 630. The control circuitry 630 is shown having various modules, which are implemented either in hardware or as one or more sequences of steps carried out on the microprocessor or other microcontroller. It is understood that the various modules of control circuitry 630 need not be separately embodied, but may be combined or otherwise implemented differently, such as in software/firmware.

The control circuitry 630 includes a pacing pulse generator 640, a pulse rate controller 644, and an intrinsic rate detector 650 which are coupled through bus 654. In one embodiment, the pacing pulse generator 640 produces pacing pulses to be delivered through at least the first electrode, where the pacing pulse generator 640 is controlled by the pulse rate controller 644 to generate pacing pulses at the pacing rate, as previously described.

The implantable cardiac rhythm management device 600 further includes a first sensor 656 coupled to input terminals 626 and 628 to allow for a bipolar cardiac signal to be sensed through the first and second electrodes 606 and 607. Alternatively, a unipolar cardiac signal could be sensed between the first electrode 606 and the housing 658 of the implantable cardiac rhythm management device 600. In addition to the first sensor 656, the implantable cardiac rhythm management device 600 further includes a second sensor 660 and a third sensor 664. In one embodiment, first and second defibrillation electrodes 610 and 612 are coupled to second sensor 660 to allow for a bipolar morphology
signal to be sensed between the electrodes. In addition, first electrode 608 and first defibrillation electrode 610 are coupled to the third sensor 664 to allow for a bipolar rate signal to be sensed between the electrodes. The pacing pulse generator 640 is coupled to at least the first electrode 606 and produces electrical pulses to be delivered to the first electrode 606, as previously described. Power to the implantable cardiac rhythm management device 600 is supplied by an electrochemical battery 668 that is housed within the device 600.

The output of each of the sensors 656, 660 and 664 is received by an arrhythmia detector 670. In one embodiment, the arrhythmia detector 670 analyzes the sensed cardiac signals for the occurrence of sensed cardiac contractions and the presence of arrhythmias. In one embodiment, the arrhythmia detector 670 analyze the cardiac signal being detected from the atrial region for the occurrence of an atrial arrhythmia. When an atrial arrhythmia is detected, one or more pulses of cardioversion and/or defibrillation energy are generated by the cardioversion/defibrillation pulse generator 672. The energy can then be delivered to the atrial region through combinations of the first defibrillation electrode 610, second defibrillation electrode 612 and housing 658 to convert the atrial arrhythmia, as previously described. Alternatively, the pacing pulse generator 640 generates antitachycardia pacing for delivery to the atria to convert the atrial arrhythmia, as previously described.

Once the atrial arrhythmia is converted, the pulse rate controller 644 controls the pacing pulse generator 640 to generate pacing pulses at a pacing rate having the initial value, as previously described. In one embodiment, the pulse rate controller 644 controls the pacing pulse generator 640 to provide the first pacing pulse of the pacing pulses at the delay after the electrical pulse, as previously described. The pulse rate controller, through the pacing pulse generator 640, provides pacing pulses to generate the set number of cardiac cycles and then decreases the pacing rate by the set amount, as previously discussed, until an intrinsic contraction is detected in the cardiac signal. The intrinsic contraction is detected by the intrinsic rate detector 650, where the intrinsic rate detector 650 also determines the intrinsic rate with the detected intrinsic contraction, as previously described. Once the intrinsic rate is
determined, the pulse rate controller 644 then increases and maintains the pacing
rate of the pacing pulses above the intrinsic rate, as previously described.

Electronic communication circuitry 680 is additionally coupled to the
control circuitry 630 to allow communication with an external controller 688. In
one embodiment, the electronic communication circuitry 680 includes a data
receiver and a data transmitter to send and receive and transmit signals and
cardiac data to and from an external programmer 688. In one embodiment, the
data receiver and the data transmitter include a wire loop antenna to establish a
radio frequency telemetric link, as is known in the art, to receive and transmit
signals and data to and from the programmer unit 688.

This application is intended to cover any adaptations or variations of the
present invention. For example, while atrial arrhythmia has been one focus of
the present subject matter, it is recognized that the same concepts and ideas can
be applied to the ventricular arrhythmias. Therefore, the foregoing discussion
for the present system is not limited to atrial arrhythmias. It is manifestly
intended that this invention be limited only by the claims and equivalents
thereof.
We Claim:

1. A pulse generator system, comprising a first electrode, a sensor to sense an intrinsic signal through the first electrode, a pulse generator that produces pulses to be delivered through the first electrode, a pulse rate controller coupled to the pulse generator, wherein the pulse generator is controlled by the pulse rate controller to generate pulses at a pulse rate, wherein the pulse rate has an initial value, and an intrinsic rate detector coupled to the pulse rate controller, and wherein the pulse generator system is characterized by:
   the pulse rate controller decreasing the pulse rate from the initial value until an intrinsic depolarization is detected in the intrinsic signal by the intrinsic rate detector, wherein the intrinsic rate detector determines an intrinsic rate using the detected intrinsic depolarization, and wherein the pulse rate controller increases the pulse rate above the intrinsic rate.

2. The system of claim 1, wherein the pulse rate controller provides pulses to generate a set number of cycles, then decreases the pulse rate by a set amount, and repeats providing pulses and decreasing the pulse rate until the intrinsic depolarization is detected in the intrinsic signal.

3. The system of claim 1, wherein the initial value of the pulse rate is set in a range of 100 to 200 pulses per minute.

4. The system of claim 1, wherein the intrinsic rate detector determines the intrinsic rate from an interval between the intrinsic depolarization and a provided pulse that immediately precedes the intrinsic depolarization.

5. The system of claim 1, where the intrinsic rate detector determines the intrinsic rate from an interval between two intrinsic depolarizations.
6. The system of claim 1, where the pulse rate controller decreases the pulse rate by increasing an interval between the provided pulses by a set value in the range of 7.5 to 10 milliseconds.

7. The system of claim 1, including an shock electrode coupled to the control circuitry, and wherein the control circuitry includes an arrhythmia detector and a shock generator, wherein the arrhythmia detector is coupled to the first electrode, and the shock generator is coupled to the shock electrode, wherein the arrhythmia detector detects an arrhythmia from the sensed intrinsic signal, the shock generator provides a shock after the detection of the arrhythmia, and wherein the pulse rate controller controls the pulse generator to provide a first pulse at a delay after the shock.

8. The system of claim 1, wherein the pulse rate controller maintains the pulse rate of the provided pulses at or above the intrinsic rate by decreasing an interval between the provided pulses by a set value in the range of 7.5 to 10 milliseconds, decreasing the pulse rate until the intrinsic depolarization is detected in the intrinsic signal by the intrinsic rate detector, and increasing the pulse rate of the provided pulses above the intrinsic rate.

9. The system of claim 1, wherein the intrinsic signal is an atrial cardiac signal.

10. A pulse delivery method, comprising:
    providing pulses after a shock, where the pulses have a pulse rate at an initial value;
    decreasing the pulse rate from the initial value;
    detecting at least one depolarization;
    determining an intrinsic rate from the at least one depolarization; and
    increasing the pulse rate above the intrinsic rate.
11. The method of claim 10, including setting the initial value of the pulse rate in a range of 100 to 200 pulses per minute.

12. The method of claim 10, wherein decreasing the pulse rate includes:
   (a) providing pulses for a set number of cycles;
   (b) decreasing the pulse rate by a set amount; and
   (c) repeating (a) and (b) until at least one intrinsic depolarization is detected.

13. The method of claim 10, wherein detecting the at least one intrinsic depolarization includes detecting the at least one intrinsic depolarization following a provided pulse, and wherein determining the intrinsic rate includes determining the intrinsic rate corresponding to an interval measured from the provided pulse to the subsequent intrinsic depolarization.

14. The method of claim 10, including:
   sensing an intrinsic signal;
   detecting an arrhythmia from the sensed intrinsic signal;
   providing an shock after detecting the arrhythmia; and
   providing a first pulse at a delay period after the shock.

15. The method of claim 10, wherein increasing the pulse rate includes maintaining the pulse rate at or above the intrinsic rate.

16. The method of claims 10 or 15, wherein maintaining the pulse rate at or above the intrinsic rate includes decreasing an interval between the provided pulses by a set value in the range of 7.5 to 10 milliseconds.

17. The method of claim 10, wherein determining the intrinsic rate from the at least one intrinsic depolarization includes determining the intrinsic rate from at least two intrinsic depolarizations.
100.

SENSE CARDIAC SIGNAL

110.

ANALYZE CARDIAC SIGNAL TO DETECT ARRHYTHMIA

120.

CONVERT ARRHYTHMIA

130.

PROVIDE PACING PULSES AT INITIAL PREDETERMINED VALUE

140.

DECREASE RATE OF PACING PULSES

150.

DETERMINE INTRINSIC CARDIAC RATE FROM DETECTED INTRINSIC CONTRACTION

160.

INCREASE PACING RATE ABOVE INTRINSIC CARDIAC RATE

FIG. 1
SENSE ATRIAL CARDIAC SIGNAL

ANALYZE ATRIAL CARDIAC SIGNAL TO DETECT ATRIAL ARRHYTHMIA

CONVERT ATRIAL ARRHYTHMIA

PROVIDE PACING PULSES AT INITIAL PREDETERMINED VALUE

DECREASE RATE OF PACING PULSES

DETERMINE INTRINSIC CARDIAC RATE FROM DETECTED INTRINSIC ATRIAL CONTRACTION

INCREASE PACING RATE ABOVE INTRINSIC CARDIAC RATE

FIG. 2
FIG. 4
A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61N1/39 A61N1/368

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5 676 687 A (AYERS GREGORY M) 14 October 1997 (1997-10-14) the whole document</td>
<td>1-5,7,9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>US 5 265 600 A (ADAMS JOHN M ET AL) 30 November 1993 (1993-11-30) the whole document</td>
<td>1-5,7,9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>EP 0 518 599 A (TELELECTRONICS NV) 16 December 1992 (1992-12-16) the whole document</td>
<td>1-9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patient family numbers are listed in annex.

**Special categories of cited documents:**

*A* document defining the general state of the art which is not considered to be of particular relevance

*E* earlier document but published on or after the international filing date

*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*O* document referring to an oral disclosure, use, exhibition or other means

*P* document published prior to the international filing date but later than the priority date claimed

**Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**Z** document member of the same patent family

Date of the actual completion of the International search: 19 February 2002

Date of mailing of the International search report: 26/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL-5203 HV Rijswijk

Tel. (+31-70) 340-2060, Fax. (+31-70) 340-3018

Authorized officer: Ferrigno, A

Form PCT/ISA/210 (second sheet) (July 1992)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CA 2205271 A1</td>
<td>11-04-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0811399 A2</td>
<td>10-12-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2205326 A1</td>
<td>04-12-1997</td>
</tr>
<tr>
<td>US 5265600 A</td>
<td>30-11-1993</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>EP 0518599 A</td>
<td>16-12-1992</td>
<td>DE 69222362 D1</td>
<td>30-10-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69222362 T2</td>
<td>29-01-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0518599 A2</td>
<td>16-12-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5292339 A</td>
<td>08-03-1994</td>
</tr>
</tbody>
</table>